---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-24-000604"
form_type: "8-K"
ticker: null
cik: "0001476963"
company_name: "Scorpius Holdings, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:29:51.185368+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scorpius Holdings reports FY2023 net loss $45.2M, Q4 revenue up 570% sequentially, going concern warning

## Summary
- FY2023 contract revenue $6.6M (vs $0.1M in 2022); Q4 2023 revenue $4.8M, a 570% sequential increase from Q3.
- Net loss attributable to Scorpius $45.2M ($1.74 per share) vs $43.4M ($1.70) in 2022.
- Cash and equivalents $2.4M as of December 31, 2023.
- Auditor includes going concern opinion due to recurring losses and lack of significant revenue or positive cash flows.
- Management expects to become cash flow positive by early 2025; over $20M in contract bookings recorded.

## SEC filing metadata
- accession: 0001079973-24-000604
- form_type: 8-K
- cik: 0001476963
- company_name: Scorpius Holdings, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/0001079973-24-000604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/scpx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-24-000604
- JSON: https://secwatch.observer/filing/0001079973-24-000604.json
- Plain text: https://secwatch.observer/filing/0001079973-24-000604.txt

## Key facts
- Earnings Releases
  Scorpius Holdings, Inc. reported the year ended December 31, 2023 results: revenue $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal, net income approximately $45.2 million, or ($1.74) per basic and diluted share, EPS ($1.74) per basic and diluted share.
  - Period: the year ended December 31, 2023
  - Revenue: $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal
  - Net income: approximately $45.2 million, or ($1.74) per basic and diluted share
  - EPS: ($1.74) per basic and diluted share
  - Result: reported results
  source text: For the year ended December 31, 2023, the Company recognized $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royalty revenue from continuing operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/0001079973-24-000604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.